How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients
© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology..
OBJECTIVES: The ASSIST study investigated prescribing in routine psoriatic arthritis (PsA) care and whether the patient reported outcome: PsA Impact of Disease questionnaire (PsAID-12), impacted treatment. This study also assessed a range of patient and clinician factors and their relationship to PsAID-12 scoring and treatment modification.
METHODS: Patients with PsA were selected across the UK and Europe between July 2021-March 2022. Patients completed the PsAID questionnaire, with the results shared with their physician. Patient characteristics, disease activity, current treatment methods, treatment strategies, medication changes and patient satisfaction scores were recorded.
RESULTS: 503 patients recruited. 36.2% had changes made to treatment, 88.8% of this had treatment escalation. Overall, the mean PsAID-12 score was higher for patients with treatment escalation; the PsAID-12 score was associated with odds of treatment escalation (OR: 1.58; p< 0.0001). However, most clinicians reported PsAID-12 did not impact their decision to escalate treatment, instead supporting treatment reduction decisions. Physician's assessment of disease activity had the most statistically significant effect on likelihood of treatment escalation, (OR = 2.68, per 1-point score increase). Escalation was more likely in patients not treated with biologic therapies. Additional factors associated with treatment escalation included: patient characteristics, physician characteristics, disease activity and disease impact.
CONCLUSION: This study highlights multiple factors impacting treatment decision making for individuals with PsA. PsAID-12 scoring correlates with multiple measures of disease severity and odds of treatment escalation. However, most clinicians reported the PsAID-12 did not influence treatment escalation decisions. PsAID scoring could be used to increase confidence in treatment de-escalation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - (2024) vom: 08. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Coyle, Conor [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ASSIST |
|---|
| Anmerkungen: |
Date Revised 09.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/rheumatology/kead679 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36682595X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36682595X | ||
| 003 | DE-627 | ||
| 005 | 20240114233232.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/kead679 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1254.xml |
| 035 | |a (DE-627)NLM36682595X | ||
| 035 | |a (NLM)38191998 | ||
| 035 | |a (PII)kead679 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coyle, Conor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. | ||
| 520 | |a OBJECTIVES: The ASSIST study investigated prescribing in routine psoriatic arthritis (PsA) care and whether the patient reported outcome: PsA Impact of Disease questionnaire (PsAID-12), impacted treatment. This study also assessed a range of patient and clinician factors and their relationship to PsAID-12 scoring and treatment modification | ||
| 520 | |a METHODS: Patients with PsA were selected across the UK and Europe between July 2021-March 2022. Patients completed the PsAID questionnaire, with the results shared with their physician. Patient characteristics, disease activity, current treatment methods, treatment strategies, medication changes and patient satisfaction scores were recorded | ||
| 520 | |a RESULTS: 503 patients recruited. 36.2% had changes made to treatment, 88.8% of this had treatment escalation. Overall, the mean PsAID-12 score was higher for patients with treatment escalation; the PsAID-12 score was associated with odds of treatment escalation (OR: 1.58; p< 0.0001). However, most clinicians reported PsAID-12 did not impact their decision to escalate treatment, instead supporting treatment reduction decisions. Physician's assessment of disease activity had the most statistically significant effect on likelihood of treatment escalation, (OR = 2.68, per 1-point score increase). Escalation was more likely in patients not treated with biologic therapies. Additional factors associated with treatment escalation included: patient characteristics, physician characteristics, disease activity and disease impact | ||
| 520 | |a CONCLUSION: This study highlights multiple factors impacting treatment decision making for individuals with PsA. PsAID-12 scoring correlates with multiple measures of disease severity and odds of treatment escalation. However, most clinicians reported the PsAID-12 did not influence treatment escalation decisions. PsAID scoring could be used to increase confidence in treatment de-escalation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ASSIST | |
| 650 | 4 | |a EQ-5D-5L | |
| 650 | 4 | |a HAQ | |
| 650 | 4 | |a PSAID | |
| 650 | 4 | |a PSAID-12 | |
| 650 | 4 | |a Patient reported outcomes | |
| 650 | 4 | |a PsA | |
| 650 | 4 | |a Psoriatic arthritis | |
| 650 | 4 | |a Quality of life | |
| 700 | 1 | |a Watson, Lily |e verfasserin |4 aut | |
| 700 | 1 | |a Whately-Smith, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Brooke, Mel |e verfasserin |4 aut | |
| 700 | 1 | |a Kiltz, Uta |e verfasserin |4 aut | |
| 700 | 1 | |a Lubrano, Ennio |e verfasserin |4 aut | |
| 700 | 1 | |a Queiro, Ruben |e verfasserin |4 aut | |
| 700 | 1 | |a Trigos, David |e verfasserin |4 aut | |
| 700 | 1 | |a Brandt-Juergens, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Choy, Ernest |e verfasserin |4 aut | |
| 700 | 1 | |a D'Angelo, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Delle Sedie, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Dernis, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Wirth, Théo |e verfasserin |4 aut | |
| 700 | 1 | |a Guis, Sandrine |e verfasserin |4 aut | |
| 700 | 1 | |a Helliwell, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Hueber, Axel |e verfasserin |4 aut | |
| 700 | 1 | |a Joven, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Koehm, Michaela |e verfasserin |4 aut | |
| 700 | 1 | |a Morales, Carlos Montilla |e verfasserin |4 aut | |
| 700 | 1 | |a Packham, Jon |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto Tasende, Jose Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Felipe Julio Ramirez |e verfasserin |4 aut | |
| 700 | 1 | |a Ruyssen-Witrand, Adeline |e verfasserin |4 aut | |
| 700 | 1 | |a Scrivo, Rossana |e verfasserin |4 aut | |
| 700 | 1 | |a Twigg, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Welcker, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Soubrier, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Gossec, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Coates, Laura C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g (2024) vom: 08. Jan. |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:08 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/kead679 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 08 |c 01 | ||